ReviewInnere Medizin (Heidelberg, Germany)2026
[Systemic lupus erythematosus-pathogenesis, clinical presentation, diagnosis, and management].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that predominantly affects women. The disease often manifests through nonspecific symptoms, such as fever, fatigue, and arthralgia; the skin and kidneys are also frequently affected. Management is guided by the treat-to-target (T2T) principle, with the goal of achieving a state of remission as quickly as possible. An increasing selection of medications is available for this purpose, the use of which is further detailed in the new S3 guideline on SLE and in new international recommendations. The objective of this article is to convey the central aspects concerning the pathogenesis, diagnosis, and management of SLE and to reduce uncertainties in dealing with affected patients.
Indexed as
Identifiers
41569326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.